Navigation Links
Top-Line Preliminary Data From Phase II/III Study of Corthera's Relaxin in Acute Heart Failure to be Presented in Satellite Symposium at AHA Scientific Sessions 2008
Date:11/3/2008

SAN MATEO, Calif., Nov. 3 /PRNewswire/ -- Top-line preliminary data from a Phase II/III clinical trial of Corthera's investigational drug relaxin for the treatment of acute heart failure will be presented next week at a satellite symposium at the American Heart Association's (AHA) Scientific Sessions 2008 in New Orleans.

John R. Teerlink, M.D., Professor of Medicine, University of California San Francisco, will present the data from the multicenter, international Pre/RELAX-AHF study as part of a symposium entitled "Tailoring Therapy to Presentation" that will focus on new approaches to the treatment of acute heart failure. The symposium will take place from 6 a.m. CST to 8 a.m. CST on Monday, Nov. 10, in the Grand Ballroom of the Sheraton New Orleans Hotel.

According to the AHA, heart failure is a costly syndrome contributing to more than 3 million hospitalizations each year in the U.S. The great majority of patients with acute heart failure have fluid accumulation in the lungs (congestion) that causes shortness of breath and other complications. For these patients, the current standard of care includes diuretics and vasodilators. Both of these classes of agents have been associated with renal impairment, hypotension and adverse outcomes.

About Relaxin

Relaxin is a naturally occurring peptide hormone that acts as a systemic and renal vasodilator. Elevated levels of relaxin modulate increases in renal and cardiac function that meet the increased hemodynamic demands of pregnancy. Consistent with this natural role of the hormone, pharmaceutically manufactured relaxin has been shown to have these effects in multiple human studies of men and non-pregnant women. Data from a pilot study in patients with heart failure support the expectation that these effects may be beneficial in relieving the signs and symptoms of heart failure.

About Corthera

Corthera Inc. is a biopharmaceutical company committed to acquiring, developing a
'/>"/>

SOURCE Corthera
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Sinovac Reports Top-Line Preliminary Phase II Results of Pandemic Influenza (H5N1) Whole Viron Vaccine
2. Telik Announces Top-Line Results From Assist-5 Trial of Telcyta(R) in Combination With Pegylated Liposomal Doxorubicin in Platinum Refractory and Resistant Ovarian Cancer
3. Memry Corporation Announces Preliminary Fiscal Fourth Quarter and 2007 Revenue
4. YM BIOSCIENCES ANNOUNCES POSITIVE PRELIMINARY RESULTS FROM PHASE I/II LUNG CANCER TRIAL OF NIMOTUZUMAB COMBINED WITH RADIATION
5. BioCryst Reports Preliminary Results From a Phase II Clinical Trial of Peramivir in Subjects With Acute Influenza
6. CryoLife Announces Preliminary Third Quarter 2007 Revenues of Approximately $21.9 Million
7. Angiotech announces preliminary third quarter financial results and updates fiscal 2007 outlook
8. Aidas Rh-Apo2L Clinical Testing Shows Preliminary Efficacy in Helping to Treat Lung Cancer, Stomach Cancer, Lymphoma, Pancreatic Cancer & Kidney Cancer
9. Tapestry Reports Third Quarter 2007 Financial Results and Preliminary Data From Its Phase 2 Prostate Cancer Trial
10. Symmetry Medical Reports Preliminary Third Quarter Revenue
11. KV Pharmaceutical Company Reports Record Revenues for Fiscal 2008 Second Quarter and Six Months on a Preliminary Basis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2009)SINGAPORE, Dec. 2 S*BIO Pte Ltd today announced data presentations on its novel oral JAK2 inhibitor, SB1518, at The American Society of Hematology 51st Annual Meeting and Exposition in New Orleans. ,
(Date:12/2/2009)NANJING, China, Dec. 2 /PRNewswire-Asia/ -- Simcere Pharmaceutical Group,("Simcere" or the "Company") (NYSE: SCR ), a leading pharmaceutical company,specializing in the development, manufacturing, a
(Date:12/2/2009)SHANGHAI, Dec. 2 /PRNewswire-Asia/ -- The world is going through,extraordinary times; markets are in turmoil and uncertainty is part of many,businesses and industries. It turns out that the pharma ind
(Date:12/2/2009)HOBOKEN, N.J., Dec. 2 According to the National Institute of Health, 40 percent to 45 percent of Americans diagnosed with diabetes already have some stage of diabetic retinopathy. Diabetic retinopat
Breaking Biology Technology:S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 2S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 3S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 4S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 5Simcere Announces 105 Drugs Included in China's National Drug Reimbursement List 2Simcere Announces 105 Drugs Included in China's National Drug Reimbursement List 3Pharma and Biotech Leaders to Converge in China at Asia Pharma R&D Leaders 2010 Summit 2Pharma and Biotech Leaders to Converge in China at Asia Pharma R&D Leaders 2010 Summit 3Study Shows Pine Bark Improves Microcirculation, Retinal Swelling And Visual Acuity In Early Diabetic Retinopathy 2Study Shows Pine Bark Improves Microcirculation, Retinal Swelling And Visual Acuity In Early Diabetic Retinopathy 3Study Shows Pine Bark Improves Microcirculation, Retinal Swelling And Visual Acuity In Early Diabetic Retinopathy 4
...wing a devastating legal rebuke, the chief executi... to pursue other business interests. , ,Jeff Cason...provider of uninterruptible power supply services,...es. Former executive vice president Charley Eaton ...was sued for copyright infringement by UPS manufac...
...part of a new contract with General Motors , the ...ill design plug-in batteries for a Saturn hybrid...hnson Controls-Saft Advanced Power Solutions will... recharged from a typical household electrical out...n recent months for JCS. In August of 2006, the Eu...
... a Wisconsin entrepreneur what,s vital to the succ...o get a shopping list as a definitive answer. Find...lth insurance, protecting intellectual property, a...replies. , ,Holding down taxes? That,s on the shor...er depends on the entrepreneur. Those who aren,t y...
Other Biology Technology:High taxes and low rates of entrepreneurship - is there a relationship? 2High taxes and low rates of entrepreneurship - is there a relationship? 3
(Date:12/3/2009)Coral reef fish can undergo a personality change in warmer water, according to an intriguing new study suggesting that climate change may make some species more aggressive. , Experiments with two spe
(Date:12/3/2009)UPTON, NY A team of scientists from the U.S. Department of Energy,s (DOE) Brookhaven National Laboratory, Harvard University, and the Indian Institute of Science has made a major step in understandin
(Date:12/2/2009)PHILADELPHIA Cigarette smoking and alcohol consumption before head and neck cancer diagnosis strongly predicts the patient,s future risk of death, according to published studies. Now, results of a ne
Breaking Biology News(10 mins):Fish with attitude: Some like it hot 2Grooving down the helix 2Grooving down the helix 3Head and neck cancer survivors who use alcohol and cigarettes have increased death risk 2Hanger Orthopedic Group Inc Reports 240 31 EPS for the Second Quarter 2009 and Raises Full Year EPS Guidance 53000 1Hanger Orthopedic Group Inc Reports 240 31 EPS for the Second Quarter 2009 and Raises Full Year EPS Guidance 53000 2Hanger Orthopedic Group Inc Reports 240 31 EPS for the Second Quarter 2009 and Raises Full Year EPS Guidance 53000 3Hanger Orthopedic Group Inc Reports 240 31 EPS for the Second Quarter 2009 and Raises Full Year EPS Guidance 53000 4Hanger Orthopedic Group Inc Reports 240 31 EPS for the Second Quarter 2009 and Raises Full Year EPS Guidance 53000 5Hanger Orthopedic Group Inc Reports 240 31 EPS for the Second Quarter 2009 and Raises Full Year EPS Guidance 53000 6Hanger Orthopedic Group Inc Reports 240 31 EPS for the Second Quarter 2009 and Raises Full Year EPS Guidance 53000 7Hanger Orthopedic Group Inc Reports 240 31 EPS for the Second Quarter 2009 and Raises Full Year EPS Guidance 53000 8Hanger Orthopedic Group Inc Reports 240 31 EPS for the Second Quarter 2009 and Raises Full Year EPS Guidance 53000 9CareFusion Form 10 Registration Statement Declared Effective 52998 1CareFusion Form 10 Registration Statement Declared Effective 52998 2CareFusion Form 10 Registration Statement Declared Effective 52998 3CareFusion Form 10 Registration Statement Declared Effective 52998 4Cell Therapeutics Inc Announces Closing of Public Offering of Common Stock and Warrants 52996 1Cell Therapeutics Inc Announces Closing of Public Offering of Common Stock and Warrants 52996 2
...hange(TM) Software Access Local ...g. 13 BIO-key International,Inc. (OTC Bulletin Bo...utions and finger based biometric identification, ...ftware Module and its acceptance by several,agenci...This contract,represents BIO-key,s first with the ...
...on,Intelligence Corporation (OTC Bulletin Board: C...of electronic signature solutions for,business pro...recognized,leader in biometric signature verificat... three and six-month periods ended June 30, 2007. ...iod ended June 30,2007 increased 24% compared to $...
...o Equity, JERICHO, N.Y., Aug. 15 bioMETRX, Inc. ...d supplier of consumer,biometric products, today a... holders of its Series B common stock warrants tha... company by August 25, 2007. The Company notified...t,has elected to pay such holders $0.12 per share,...
Other Biology News:BIO-key(R) Announces Contracts for New Criminal Justice Data Sharing Solution 2BIO-key(R) Announces Contracts for New Criminal Justice Data Sharing Solution 3Communication Intelligence Corporation Reports Second Quarter 2007 Financial Results 2Communication Intelligence Corporation Reports Second Quarter 2007 Financial Results 3Communication Intelligence Corporation Reports Second Quarter 2007 Financial Results 4Communication Intelligence Corporation Reports Second Quarter 2007 Financial Results 5bioMETRX, Inc. Calls Series B Warrants 2
...Description: Proteinase K is a highly active and s...ations purified from the fungus T. album. It cleav...up of N-substituted hydrophobic aliphatic and arom...e protease. Proteinase K is useful in purifying hi...
..., high throughput, water bath thermal cycler capab...oplates. This equates to 9,216 reactions per run w...y transfers a basket of plates between three water... are considerably faster than those of peltier blo...
...tidine Dideoxycytidine is a cytidine analog that ...viral activity. Immunogen: Chemical / Small Mol...ficity of the ddC antiserum was determined by calc...ddC analog at the 50% intercept of the respective ...
MSC.12 class II safety cabinet (Type A1) - CE Marked (230V / 50Hz) from Thermo Scientific
Biology Products: